A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.

Trial Profile

A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs ALT 801 (Primary) ; Cisplatin; Gemcitabine
  • Indications Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Oct 2016 According to Altor BioScience Corporation media release, Status changed from active, no longer recruiting to completed.
    • 11 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top